GPD2 and type 2 diabetes mellitus: Based on the effects of total-body knockout of mGPDH in mice, MacDonald and coworkers suggested that adverse effects in tissues where the level of mGPD is much higher than that in the liver could prevent the therapeutic administration of metformin in type 2 diabetes, if it actually inhibited mGPDH [86].